JNK Inhibitors for Use in Treating Spinal Muscular Atrophy

Technology #d-1054

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Dr. Laxman Gangwani
Dr. Gangwani states the goal of his proposed research project is to investigate the role of zinc finger protein XPR1 in neurodegeneration and as a modifier of spinal muscular atrophy. Dr. Gangwani has demonstrated a record of successful and productive research projects in an area of high relevance and significance for SMA, and he feels his expertise and experience have prepared him to lead the current proposed project. Dr. Gangwani has received numerous awards and honors in India, as well as the United States. Dr. Gangwani has also been an invited speaker at many national and international events for the past seven years.
External Link (elpaso.ttuhsc.edu)
Managed By
David McClure
Director Licensing 806-834-5899
Patent Protection

\Jnk inhibitors for use in treating spinal muscular atrophy

US Patent Pending 13,321,029

Mutation of the Survival Motor Neuron1 (SMN1) gene causes spinal muscular atrophy (SMA), a progressive neurodegenerative disorder which is the leading cause of infant death in the U.S.  Degeneration of spinal motor neurons caused by SMN deficiency results in muscle atrophy and death.  The JNK3 pathway mediates neurodegeneration in SMA.  JNK3-deficiency or treatment with JNK inhibitors reduces degeneration of neurons caused by low levels of SMN.   


Market Applications:

  • Pharmaceuticals
  • Health Care


Features, Benefits & Advantages:

The brain specific isoform (JNK3) of c-Jun NH2-terminal kinase (JNK) has been found to mediate the degeneration of spinal motor neurons caused by SMN deficiency in spinal muscular atrophy (SMA). Moreover, JNK inhibitors reduce degeneration of neurons lacking SMN.  The JNK signaling pathway can therefore mediate neurode-generation in SMA and represents a therapeutic target for treatment of SMA.

  • JNK3-deficiency prevents neuron loss and reduces muscle degeneration
  • JNK pathway represents a potential therapeutic target for treatment of SMA


Development Stage:

The technology has been produced and tested.  Preliminary experimental data have provided proof of concept.